Literature DB >> 28395979

Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model.

Mariama Akodad1, Jérémy Fauconnier2, Pierre Sicard2, Fabien Huet1, Florence Blandel2, Annick Bourret2, Pascal de Santa Barbara2, Sylvain Aguilhon3, Marion LeGall2, Gérald Hugon2, Alain Lacampagne2, François Roubille4.   

Abstract

BACKGROUND: Inflammation is deeply involved in the pathophysiology of ischemia-reperfusion (I/R) lesions and ventricular remodeling due to an acute myocardial infarction (AMI). Colchicine as a pleiotropic anti-inflammatory molecule may exert cardioprotective effects under acute ischemia. Here, we aimed to evaluate the impact of colchicine on reperfusion injury in a mouse model.
METHOD: Myocardial ischemia/reperfusion (I/R) injury was induced in C57BL/6 male mice, after 45min ligation of the left coronary artery followed by reperfusion. 400μg/kg of colchicine or the vehicle was administrated intraperitoneally (i.p.) 25min before the reperfusion (blinded administration). Mice were sacrificed at 24h after the acute myocardial ischemia (AMI) and the infarct size was determined. Circulating level of troponin and cytokines profile were assessed 4h after the AMI. An echocardiography was performed in a follow-up group mice, 48h and 8weeks after the AMI.
RESULTS: The infarct size was reduced in colchicine treated mice (39.8±3.5% versus 52.9±3.2%, p<0.05). Troponin was significantly lower in the colchicine treated mice (7015.7±1423.7pg/mL, n=5 vs 30,723.7±7959.9pg/mL in the placebo group, n=6; p<0.0001). Fibrosis was decreased in the Colchicine group (24.51±3.13% vs 11.38±2.46%, p=0.03). In the follow-up group mice (n=8), there were no differences between mice treated with placebo (n=9) and mice treated with colchicine (n=9) regarding to cardiac remodeling parameters but outflow approximated by the ITV was higher in the colchicine group.
CONCLUSION: In conclusion, colchicine allowed a significant reduction of infarct size in mice, improves hemodynamic parameters and decrease cardiac fibrosis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28395979     DOI: 10.1016/j.ijcard.2017.03.126

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

Review 1.  Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?

Authors:  Thomas F Whayne
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

2.  Colchicine Inhibits NETs and Alleviates Cardiac Remodeling after Acute Myocardial Infarction.

Authors:  Yue-Wei Li; Si-Xu Chen; Ying Yang; Zeng-Hui Zhang; Wei-Bin Zhou; Yu-Na Huang; Zhao-Qi Huang; Jia-Qi He; Ting-Feng Chen; Jing-Feng Wang; Zhao-Yu Liu; Yang-Xin Chen
Journal:  Cardiovasc Drugs Ther       Date:  2022-07-28       Impact factor: 3.947

Review 3.  Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury.

Authors:  Stefano Toldo; Adolfo G Mauro; Zachary Cutter; Antonio Abbate
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-31       Impact factor: 4.733

4.  MiR-23a Is Involved in Myocardial Ischemia/Reperfusion Injury by Directly Targeting CX43 and Regulating Mitophagy.

Authors:  Lina Wang; Qing Li; Jiayu Diao; Lin Lin; Jin Wei
Journal:  Inflammation       Date:  2021-03-02       Impact factor: 4.092

Review 5.  Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy.

Authors:  Esther Forkosh; Ariel Kenig; Yaron Ilan
Journal:  Pharmacol Res Perspect       Date:  2020-08

Review 6.  Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction.

Authors:  Max J M Silvis; Evelyne J Demkes; Aernoud T L Fiolet; Mirthe Dekker; Lena Bosch; Gerardus P J van Hout; Leo Timmers; Dominique P V de Kleijn
Journal:  J Cardiovasc Transl Res       Date:  2020-07-09       Impact factor: 4.132

7.  Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism.

Authors:  Fabien Huet; Jérémy Fauconnier; Marion Legall; Pierre Sicard; Catherine Lozza; Alain Lacampagne; François Roubille
Journal:  Future Sci OA       Date:  2020-11-23

8.  Knockdown of circROBO2 attenuates acute myocardial infarction through regulating the miR-1184/TRADD axis.

Authors:  Tian-Ping Chen; Nai-Ju Zhang; Hong-Ju Wang; Si-Gan Hu; Xu Geng
Journal:  Mol Med       Date:  2021-03-03       Impact factor: 6.354

9.  Colchicine to Prevent Sympathetic Denervation after an Acute Myocardial Infarction: The COLD-MI Trial Protocol.

Authors:  Fabien Huet; Quentin Delbaere; Sylvain Aguilhon; Valentin Dupasquier; Delphine Delseny; Richard Gervasoni; Jean-Christophe Macia; Florence Leclercq; Nidal Jammoul; Sandra Kahlouche; Sonia Soltani; Fanny Cardon; Anne-Marie Dupuy; Jean-Paul Cristol; Denis Mariano-Goulart; Myriam Akodad; Nicolas Nagot; François Roubille
Journal:  Medicina (Kaunas)       Date:  2021-09-30       Impact factor: 2.430

Review 10.  Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling.

Authors:  Shichun Shen; Zhen Wang; Haozhong Sun; Likun Ma
Journal:  Med Sci Monit       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.